PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia (2017)
Source: The Journal of Clinical Pharmacology. Unidade: FM
Subjects: LIPÍDEOS, ANTICORPOS MONOCLONAIS, HIPERCOLESTEROLEMIA, DOENÇAS GENÉTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ITO, Matthew K. e SANTOS, Raul D. PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. The Journal of Clinical Pharmacology, v. 57, n. 1, p. 7-32, 2017Tradução . . Disponível em: http://onlinelibrary.wiley.com/doi/10.1002/jcph.766/epdf. Acesso em: 21 maio 2024.APA
Ito, M. K., & Santos, R. D. (2017). PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. The Journal of Clinical Pharmacology, 57( 1), 7-32. doi:10.1002/jcph.766NLM
Ito MK, Santos RD. PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia [Internet]. The Journal of Clinical Pharmacology. 2017 ; 57( 1): 7-32.[citado 2024 maio 21 ] Available from: http://onlinelibrary.wiley.com/doi/10.1002/jcph.766/epdfVancouver
Ito MK, Santos RD. PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia [Internet]. The Journal of Clinical Pharmacology. 2017 ; 57( 1): 7-32.[citado 2024 maio 21 ] Available from: http://onlinelibrary.wiley.com/doi/10.1002/jcph.766/epdf
